Ann Louw Selected Research

cyclopia sequence

1/2023	Cyclopia extracts act as selective estrogen receptor subtype downregulators in estrogen receptor positive breast cancer cell lines: Comparison to standard of care breast cancer endocrine therapies and a selective estrogen receptor agonist and antagonist.
1/2022	Combinatorial treatments of tamoxifen and SM6Met, an extract from Cyclopia subternata Vogel, are superior to either treatment alone in MCF-7 cells.
1/2018	Chemoprevention of LA7-Induced Mammary Tumor Growth by SM6Met, a Well-Characterized Cyclopia Extract.
10/2016	The phytoestrogenic Cyclopia extract, SM6Met, increases median tumor free survival and reduces tumor mass and volume in chemically induced rat mammary gland carcinogenesis.
5/2013	Phytoestrogenic potential of Cyclopia extracts and polyphenols.
1/2013	Cyclopia extracts act as ERα antagonists and ERβ agonists, in vitro and in vivo.
11/2008	Selective extraction of Cyclopia for enhanced in vitro phytoestrogenicity and benchmarking against commercial phytoestrogen extracts.
5/2007	Evaluation of the phytoestrogenic activity of Cyclopia genistoides (honeybush) methanol extracts and relevant polyphenols.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ann Louw Research Topics

Disease

8	cyclopia sequence 01/2023 - 05/2007
5	Breast Neoplasms (Breast Cancer) 01/2023 - 05/2007
5	Inflammation (Inflammations) 11/2022 - 11/2005
4	Neoplasms (Cancer) 01/2023 - 10/2016
1	Insulin Resistance 11/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Immune System Diseases (Immune Disorders) 01/2022
1	Glucocorticoid Receptor Deficiency 01/2021
1	Carcinogenesis 10/2016
1	Hepatocellular Carcinoma (Hepatoma) 11/2010

Drug/Important Bio-Agent (IBA)

3	GlucocorticoidsIBA 11/2022 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2010
2	TeaIBA 01/2023 - 01/2013
2	Fulvestrant (Faslodex)FDA Link 01/2023 - 01/2018
2	Estrogen ReceptorsIBA 01/2023 - 01/2018
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 11/2022 - 11/2010
2	Tamoxifen FDA LinkGeneric 01/2022 - 01/2018
2	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2021 - 01/2018
2	Estrogens (Estrogen)FDA Link 01/2018 - 01/2013
2	PolyphenolsIBA 05/2013 - 05/2007
2	Phytoestrogens (Phytoestrogen)IBA 01/2013 - 11/2008
1	afimoxifene (hydroxytamoxifen)IBA 01/2023
1	Selective Estrogen Receptor Modulators (SERM)IBA 01/2023
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2023
1	Aromatase InhibitorsIBA 01/2023
1	Estrogen Receptor alphaIBA 01/2023
1	Estrogen Receptor betaIBA 01/2023
1	Plasminogen Activator Inhibitor 1IBA 11/2022
1	CytokinesIBA 11/2022
1	Drug CombinationsIBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	hydroxide ionIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	LipidsIBA 01/2018
1	Letrozole (Femara)FDA LinkGeneric 01/2018
1	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 10/2016
1	Estradiol Congeners (Synthetic Estrogens)IBA 01/2013
1	Interleukin-6 (Interleukin 6)IBA 11/2010
1	Glucose (Dextrose)FDA LinkGeneric 11/2010
1	Messenger RNA (mRNA)IBA 11/2010
1	Methanol (Carbinol)IBA 05/2007
1	Dexamethasone (Maxidex)FDA LinkGeneric 11/2005

Therapy/Procedure

3	Therapeutics 01/2023 - 01/2018
2	Chemoprevention 01/2018 - 10/2016
1	Traction 01/2022